ECM Composite Prosthetic Valve Leaflets for Flow Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medical graft materials derived from extracellular matrix (ECM) lack improved biocompatibility and functionality for applications such as prosthetic valves, particularly in addressing venous insufficiencies and valve deficiencies, where existing ECM materials do not effectively restrict retrograde blood flow while allowing antegrade flow.
Innovation Solution
A prosthetic valve device comprising an extracellular matrix composite formed by depositing a second biosynthetically-derived ECM material onto a first ECM material, which is then isolated and formed into leaflets for implantation in bodily passages, allowing for customizable configurations and enhanced biocompatibility through cell culture and decellularization processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a first extracellular matrix material is used as a base graft material, then structural support and framework are provided, but biocompatibility and functional performance are insufficient
Solution Approach 1:
The patent applies composite materials by combining a first extracellular matrix material (such as decellularized tissue matrix) with a second biosynthetically-deposited extracellular matrix material (such as collagen, elastin, or proteoglycans secreted by cultured cells). This composite structure provides both the structural support of the base material and the enhanced biocompatibility and functionality of the biosynthetically-deposited material, resolving the contradiction between reliability and material complexity.
Solution Approach 2:
The patent employs preliminary action by culturing cells on the first extracellular matrix material before implantation, allowing the cells to biosynthetically deposit the second extracellular matrix material onto the base material in advance. This pre-conditioning of the graft material with biosynthetically-deposited components enhances biocompatibility before the material is implanted, addressing the reliability concern while maintaining a manageable process complexity.
2Reliability
If ECM material is used for prosthetic valve leaflets, then structural framework is provided, but effective restriction of retrograde blood flow is not achieved
Solution Approach 1:
The patent applies dynamics by creating valve leaflets with asymmetric thickness distribution through the biosynthetically-deposited extracellular matrix material. The leaflets are formed to be thicker at the free edge and thinner at the attachment region, allowing dynamic optimization of flow restriction at the free edge while maintaining flexibility and proper coaptation at the attachment region. This dynamic structural variation enables effective retrograde flow restriction without complicating the manufacturing process.
Solution Approach 2:
The patent employs local quality by concentrating the biosynthetically-deposited extracellular matrix material specifically at regions requiring enhanced functionality, such as the free edge of the leaflets where flow restriction is most critical. This localized enhancement of material properties improves valve function without requiring complex manufacturing processes throughout the entire leaflet structure.
3Reliability
If cells are cultured on ECM material to deposit biosynthetically-derived material, then biocompatibility is improved, but manufacturing process complexity increases
Solution Approach 1:
The patent applies self-service by utilizing the natural biosynthetic capabilities of cultured cells to deposit extracellular matrix material onto the base graft. Rather than requiring complex external application processes, the cells themselves perform the deposition function through their natural metabolic activities, simplifying the overall manufacturing process while enhancing biocompatibility through the biosynthetically-deposited material.
Solution Approach 2:
The patent employs an intermediary approach by using cultured cells as mediators between the first extracellular matrix material and the biosynthetically-deposited second material. The cells serve as a bridge that naturally synthesizes and deposits the second extracellular matrix material onto the base material, simplifying the manufacturing process compared to direct application methods while achieving enhanced biocompatibility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ECM composite valve devices effectively restrict retrograde blood flow while allowing antegrade flow, providing improved biocompatibility and functionality for treating venous insufficiencies and valve deficiencies by promoting tissue integration and angiogenesis.
Implementation Method 1
a second, biosynthetically-deposited extracellular matrix material on the surface
Data Source
AI summary
Described are preferred prosthetic valve devices including a first extracellular matrix material having a second extracellular matrix material deposited thereon. The preferred materials are made by culturing cells in contact with an extracellular matrix graft material in a fashion to cause the cells to biosynthesize and deposit extracellular matrix components on the material. The cells are then removed to provide the extracellular matrix composite material. In preferred embodiments, the prosthetic valve devices are configured for use in vascular applications.